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Narcolepsy is characterized by excessive daytime 
sleep and cataplexy. Sleep paralysis and hypnago-
gic hallucinations can be added to this clinical pic-
ture1,2. Narcolepsy involves an unknown physiopa-
thology but with a known association with the HLA 
DQB1*06023 allele3. This would fortify the hypothe-
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ABSTRACT - Narcolepsy is characterized by excessive daytime sleep and cataplexy. Little is known about 
the possible difference in pathophysiology between patients with or without cataplexy.  Obje�tive: To 
quantify T CD4, T CD8 and B lymphocytes in subgroups of patients with narcolepsy and the presence or ab-
sence of the HLA-DQB1*0602 allele between groups.  Method: Our study was prospective and controlled 
(transversal) with 22 narcoleptic patients and 23 health control subjects. Patients underwent an all-night 
polysomnographic recording (PSG) and a multiple sleep latency Test (MSLT). The histocompatibility anti-
gen allele (HLA-DQB1*0602), T CD4, CD8 and B lymphocytes were quantified in control subjects and in 
narcoleptics.  Results: The HLA-DQB1*0602 allele was identified in 10 (62.5%) of our 16 cataplexic sub-
jects and in 2 (33.3%) of the 6 patients without cataplexy (p=0.24). In control subjects, HLA-DQB1*0602 al-
lele was identified in 5 (20%). A significant decrease in T CD4 and B lymphocytes was found in narcoleptic 
patients with recurrent cataplexy when compared with our patients without cataplexy.  Con�lusion: Au-
toimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis were associated with a 
decrease in sub-group of T CD4 and B lymphocytes. A drop in B lymphocytes count in reumathoid arthri-
tis might, it is posited, be correlated to the presence of HLA-DRB1 allele along with an overall worsened 
outcome of the affliction. The theory of an increase in consumption of B lymphocytes over the maturation 
phase has likewise been put forward. Our study reinforces the view that narcolepsy should be considered 
from an immunological perspective.
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estudo dos linfócitos t Cd4, Cd8 e B em pacientes com narcolepsia
ReSUMO - A narcolepsia é caracterizada por sonolência excessiva diurna e cataplexia. Pouco se sabe sobre 
as diferenças fisiopatológicas entre pacientes com e sem cataplexia.  Objetivo: Quantificar os linfócitos T 
CD4, T CD8 e B e a presença do alelo HLA-DQB1*0602 nos subgrupos de pacientes com narcolepsia.  Mé�
todo: O estudo foi prospectivo e controlado (transversal) com 22 pacientes portadores de narcolepsia e 23 
sujeitos controle. Os pacientes realizaram polissonografia (PSG) de noite inteira e teste de múltiplas latên-
cias do sono (TMLS). O alelo do antígeno de histocompatibilidade (HLA-DQB1*0602) e os linfócitos T CD4, 
T CD8 e B foram quantificados nos pacientes e sujeitos controle.  Resultados: O alelo HLA-DQB1*0602 foi 
encontrado em 10 (62,5%) dos 16 pacientes com cataplexia e em 2 (33,3%) dos 6 pacientes sem cataplexia 
(p=0,24). Nos sujeitos controle, o alelo HLA-DQB1*0602 foi encontrado em 5 sujeitos (20%). Um aumen-
to significativo de linfócitos T CD4 e uma diminuição de linfócitos B foi observado no grupo de pacien-
tes com cataplexia freqüente quando comparado ao grupo de pacientes sem cataplexia.  Con�lus�o: Do-
enças auto-imunes como lupus eritematoso sistêmico e artrite reumatóide têm sido associadas com dimi-
nuição de linfócitos T CD4 e B. Na artrite reumatóide, diminuição de linfócitos B e presença do alelo HLA-
DRB1 tem sido associada a pior evolução. Para essa doença, a teoria de um maior consumo de linfócitos B 
em suas fases de maturação tem sido aventada. Os achados do nosso estudo reforçam a teoria imunoló-
gica da narcolepsia.
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sis of a genetic origin. Other pathophysiological hy-
potheses derive from the environment, infections 
and the immunological system. 
Abnormalities in the neurotransmission of hypo-
cretin were recently described in patients with nar-
colepsy4. Hypocretin is a neuropeptide synthesized by 
neurons whose cell bodies are located in the lateral 
hypothalamus. Their function is to maintain wakeful-
ness. The association of hypocretin to dopaminergic 
pathways in frontal brain and noradrenergic path-
ways in the brain stem is well established. The small-
er concentration of hypocretin in cerebral spinal flu-
id has only been characterized in narcoleptics with 
cataplexy5. In an immuno-hystochemical study, a re-
duction in the quantity of hypocretinergic cells of 
the lateral hypothalamus was observed, upon autop-
sy, in patients with cataplexy6. Immunological theo-
ry is based on the possible self-aggression of hypo-
cretin cells in the hypothalamus. This self-aggression 
and subsequent loss in cells would result in a drop of 
hypocretin concentration which would in itself lead 
to narcolepsy7. As the HLA DQB1*0602 allele is prev-
alent in narcoleptics and as it is also associated with 
some known auto-immune diseases, the immnologi-
cal theory therefore seems to gain impetus.
Patients with frequent outbursts of cataplexy 
highlight a greater prevalence of the HLA DQB1*0602 
allele along with a marked diminution of hypocre-
tin in the cerebral spinal fluid when compared with 
patients with absence of cataplexy. There is a lack of 
immunological studies in the literature which focus 
on patients with narcolepsy where the clinical and 
laboratory differences were assessed8-11.   
method 
The study was prospective and controlled (transversal) 
and was undertaken between November 2003 and Febru-
ary 2005 at the Sleep Disorders Institute, Department of 
Psychobiology, UNIFeSP - ePM, São Paulo. 
The study received the seal of approval from the ethics 
and Research Committee of UNIFeSP, identified by the regis-
tered code number 113�/03. All patients willingly agreed to 
participate in the study and signed the term of free consent.
Twenty three control subjects (14 male; age 35.2±14.6 
years ±Se) without excessive daytime sleepiness and 22 nar-
coleptics (12 male; age 40.�±14.8 years ±Se) who attended 
the outpatients’ unit for hypersomnolence were assessed. 
All narcoleptic patients were diagnosed according to Inter-
national Classification of Sleep Disorders (ICS) criteria2,12-14. 
Patients were divided into 3 subgroups: one with frequent 
cataplexy (more than 1 attack per month, n=6), one with 
rare cataplexy (less than 1 attack per month, n=10) and the 
third without cataplexy (absence of attacks, n=6). 
Peripherical blood samples were taken during morn-
ing fasting and were immediately sent for laboratory anal-
ysis for all subjects in the study. Identification of the pres-
ence of HLA DQB1*0602 allele in patients and in control 
subjects was also undertaken at this juncture. The study in-
cluded a quantification of total T, T CD4, T CD8 and B-lym-
phocytes in 22 patients with narcolepsy as well as in our 23 
control subjects.
Patients and control subjects who had an acute illness 
or displayed a type of any chronic illness in an active form 
were excluded from the study. Subjects who had been in-
gesting immunodepressants, stimulants or depressants and 
drugs or who were involved in alcohol or chemical sub-
stance abuse were also excluded from the study. 
�olyso�nography (�SG) – An all-night standard poly-
somnographic recording for all narcoleptic patients was un-
dertaken at our sleep laboratory. On average, the record-
ing began at 10 pm and was concluded at 6 am. 
Sleep stages were analyzed according to Rechtschaffen 
and Kales12. Respiratory events were evaluated according to 
the recommendations of the 1��� Task Force of the Amer-
ican Academy of Sleep Medicine. Arousals and periodic 
movements of lower members were analysed according to 
the ASDA (1��2) and AASM (1���) criteria respectively13. 
Multiple sleep laten�y test (MS�T) – Patients were wo-
ken up at 6 am following the all-night PSG. All electrodes 
of the previous night, except for eeG, eOG and eMG, were 
detached. The MSLT started at 8 am and, at 2-hour inter-
vals, a total of 5 PSG recordings lasting 20 minutes each 
were undertaken. The rationale behind this approach was 
to quantify the average sleep latency and to evaluate the 
presence of ReM sleep. The diagnosis of narcolepsy is ad-
vanced when two or more episodes of ReM Sleep (SOReM) 
during the five naps have been observed. An average of 
the sleep latencies equal to or less than 10 minutes charac-
terizes day time sleepiness. excessive diurnal somnolence is 
viewed to be 5 minutes or less of sleep latency1 4. 
��ADQ�1* 0602 allele analysis – HLADQB1*0602 allele 
analysis was carried out in the Genetic Laboratory attached 
to our Sleep Institute. The presence of DQB1*0602 was de-
termined using the following procedure: The DNA was ex-
tracted from the white blood cells and the region where 
the DQB1*0602 allele is located was amplified by a polim-
erase chain reaction (PCR) using of DQBF (5’- CCCGCAGAG-
GATTTCGTGTT - 3’) and DQBR (5’- AACTCCGCCCGGGTCCC 
- 3’) primers. 
These primers amplified DQB 1 *0602 and also the rare 
DQB1*0610, DQB1*0613 and DQB1*0614 alleles as a prod-
uct of 218 basic pairs. 
As an internal control for amplifications was used in the 
same PCR reaction. The following primers which only am-
plify exon 3 of the gene DRBI: eX3f (5’-TGCCAAGTGGAG-
CACCCAA - 3’) and eX3r (5’- GCATCTTGCTCTGTGCAGAT - 
3’) were used. PCR analyses were performed using 35 cycles 
of �5ºC for 30 seconds, 35 cycles of 63ºC for 30 seconds and 
35 cycles of 72ºC for 60 seconds. 
�y�pho�yte subset typing – Cells of the lymphocyte 
population were stained with antibodies directly labeled 
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Table 2. �olyso�nographi� data of our patients with nar�olepsy.
Polysomnography Patients without 
cataplexy (CA) 
n=6
Patients with rare 
cataplexy (CR) 
n=10
Patients with fre-
quent cataplexy (CF) 
n=6
t student test  
p value
Sleep efficiency (%±Se) 88.�5±1.8 71.5±16.3 83.7±14.6 p>0.05
Sleep latency (minutes±Se) 7.�±5.3 * 2.2±15 1.6±1.67 * p=0.031
ReM sleep latency (minutes±Se) �5.3±5.3 73.5±48 ��.5±74 p>0.05
Stage1 (%±Se) 5.65±4.5 4.45±4.6 5.17±4.1 p>0.05
Stage 2 (%±Se) 5�.15±�.2 61.45±6.8 56.7±6.1 p>0.05
Stages 3 and 4 (%±Se) 16.68±5.1 15.78±8.3 16±3.5 p>0.05
ReM (%±Se) 1�.46±4.6 1�.28±5.8 21.�±6.3 p>0.05
Arousal (hour±Se) 1�.3±28 10±7 12.2±20 p>0.05
Apnea-hypopnea index (AHI±Se) 6.3±1.1 5.7±4 7.4±4.8 p>0.05
Table 3. Multiple sleep laten�y test data of our patients with nar�olepsy.
Multiple sleep latency test without cataplexy  
n=6
with rare cataplexy  
n=10
with frequent cataplexy  
n=6
Sleep latency (minutes±Se) 2.5±1.2 2.�±1.4 3.4±1.3
2 SOReM 5 7 2
3 SOReM 0 0 0
4 SOReM 0 0 2
5 SOReM 1 3 2
Table 4. Co�parison of the ly�pho�ytes subgroups between patients with nar�olepsy with and without ��A DQ�1*0602 allele.
Lymphocytes Control subjects 
n=23
Narcoleptic patients without 
the HLA DQB1*0602 allele 
n=10
Narcoleptic patients  
with the HLA DQB1*0602 allele 
n=12
t student test 
p value
T 1524±433 1305.4±484 1718.25±5�7.2 p>0.05
T CD4 �10.8±316 818.1±337 ��2.7±234 p>0.05
T CD8 480±180.7 408±185 68�±514.1 p>0.05
B 285±125 235±�8.6 324±152.6 p>0.05
Table 5. Co�parison of ly�pho�ytes between �ontrol subje�ts and groups of patients with nar�olepsy.
Lymphocytes Control subjects Patients without  
cataplexy
Patients with  
rare cataplexy
Patients with  
frequent cataplexy
t student test  
p value
T 1524±433 1712.8±282 1458±811 1468.5±26� p>0.05
T CD4 �10.8±316 10�7.5±11�.1* 850.5±378.1 834±175 * *p=0.012
T CD8 480±180.7 572±222 566.7±587.� 543.8±23�.5 p>0.05
B 285±125 37�±130 ** 270±140 212±86.2 ** **p=0.026
Table 1. De�ographi� �hara�teristi�s of subgroups of nar�olepti� patients.
Patients without cataplexy 
A
Patients with rare cataplexy  
B
Patients with frequent cataplexy 
C
Age (years±Se) 38.8±15.6 47±5.3 32±5.1
Sex 
  M 
  F
 
2 
4
 
3 
7
 
1 
5
Statistical analysis (t student test): AXB (sex p=0.80 and age p=0.11); BXC (sex p>0.50 and age p=0.6�) and AXC (sex p>0.50 and age p=0.47).
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with fluoroisothiocyanate (FITC) or phycoerythrine (Pe) and 
analyzed by FACScan (Becton �� Dickinson, Heidelberg, Ger-
many). we used double staining with monoclonal antibod-
ies (Dianova, Hamburg, Germany), CD4-Pe conjugated IOT4, 
CD8-FITC conjugated IOT8, CD45-FITC conjugated IOL2, and 
CD2�-FITC conjugated IOT2�.
Statisti�al analysis – variable distribution was verified 
using the Kolmogorov-Smirnov test with values presented 
as averages and standard deviation. 
 The Chi-squared test was used to test the homogeneity 
of groups of narcoleptic patients and control subjects. The 
Fischer test was used to test the homogeneity of subgroups 
of narcoleptic patients. The t student test for independent 
samples was used for comparison of subpopulations of lym-
phocytes and age between the groups. Statistical signifi-
cance was attributed to p≤0.05. 
results
The groups of narcoleptic patients and control 
subjects were similar regarding age and sex (sex p= 
0.66; age p=0.20). Patients with narcolepsy were di-
vided into three groups, as outlined in the introduc-
tion (Table 1). All of the patients answered the ep-
worth questionnaire with a maximum of 22 and a 
minimum of � points, with an average of 18.3±3.2. 
No difference in the sleepiness scale between the 
groups of patients could be noted.
The results of the PSG recordings of our patients 
are listed in Table 2. The sleep latency in patients 
with frequent cataplexy was smaller than in patients 
without cataplexy (Table 3). 
 The prevalence of the HLA DQB1*0602 allele was 
different between the control subjects and narcolep-
tic groups: p<0.001 for control subjects versus narco-
leptics with frequent cataplexy, p<0.001 for control 
subjects versus patients with rare cataplectic attacks 
and p=0.005 between control subjects versus patients 
withouth cataplexy. 
Additionally, a statistical difference in relation to 
the presence of the HLA allele was observed between 
the groups of patients: p<0.0001 for patients with 
rare cataplectic attacks versus patients with frequent 
cataplexy, p<0.001 between patients without cata-
plexy versus patients with frequent cataplexy (Fig-
ure). No difference was noted between patients with 
rare and absent cataplectic attacks p=0.37.
we failed however to note a statistical difference 
between the subgroups of lymphocytes in control 
subjects against narcoleptics or between the groups 
of narcoleptics themselves concerning the presence 
or not of the HLA DQB1*0602 allele (Table 4). 
Differences between the subgroups of T CD4 and 
B lymphocytes subgroups were observed between 
narcoleptic patients without cataplexy and the group 
of patients with frequent cataplexy: p=0.012 for T 
CD4 and p=0.026 for B lymphocytes (Table 5).
disCussion
There has been sound headway made in under-
standing the pathophysiology of narcolepsy. The 
greater prevalence of the HLA DQB1*0602 allele 
in patients with narcolepsy with cataplexy is well 
known15. The discovery of hypocretin, with a function 
of maintenance of wakefulness, and its reduction by 
cell loss in the lateral hypothalamus in patients with 
frequent cataplexy, is one possible explanation for 
daytime sleepiness4. 
Although lymphocytes have a key function re-
garding immunology mechanism, no specific altera-
tions have been shown in patients with narcolepsy. 
Previous studies compared control-subject groups 
with narcoleptics and the presence of or lack of the 
HLA DQB1*0602 allele. None of the studies reviewed 
concentrated on subgroups of patients7-10. 
Our study showed that the prevalence of the HLA 
DQB1*0602 allele had increased in the narcoleptic 
population, being unanimous in patients affected by 
frequent cataplexy. This finding concurs with those 
of a previous study16. The quantification of T CD4 
and CD8 and B lymphocytes failed to highlight a 
statistical difference between control subjects and 
patients with narcolepsy when the comparison was 
performed between patient groups with the pres-
ence of or absence of the HLA allele. However, the 
quantity of T CD4 and B lymphocytes cells was signifi-
catively reduced in the group of narcoleptic patients 
with frequent cataplexy when compared to patients 
without cataplexy (p=0.012 and p=0.026 respective-
ly). One hypothesis to explain the above results is the 
observation of commorbidities associated with narco-
lepsy, such as a significant incidence of depression17. 
It is known that depression is associated with higher 
Figure. �resen�e of ��A DQ�1*0602 allele.
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plasma level of corticotrophines with an alteration of 
the cell immunological system18. Unfortunately, given 
that our patients were not systematically evaluated 
for depression, we are unable to verify, first-hand, 
this hypothesis. 
Moreover, some autoimmune illnesses such as 
systemic lupus erythematosus and rheumatoid ar-
thritis present a drop in T CD4 and B lymphocytes 
subgroups. The diminution of the population of lym-
phocytes B in rheumatoid arthritis can be correlated 
with the presence of the HLA DRB1 allele1�. One hy-
pothesis to explain these findings looks at the great-
er consumption of lymphocytes in some of the phases 
of cell maturation20,21. 
The association of the HLA DRB1 allele and re-
duction in T CD4 and B lymphocytes in patients with 
rheumatoid arthritis1� and multiple sclerosis21 can 
point to an immunological theory for narcolepsy. The 
HLA DRB1 allele are more prevalent in patients with 
a severe form of rheumatoid arthritis. Similarly our 
study highlighted a relatively larger quantity of CD4 
and B lymphocytes in patients with frequent cata-
plexy compared with patients without cataplexy sug-
gesting, as for the rheumatoid arthritis, a bimodal 
presentation of the disease. 
Patients with multiple sclerosis presented with an 
infiltration of B lymphocytes in the brain. Patients 
with this disease also have a higher prevalence of the 
HLA DQB1*0602 allele20. Clinical and laboratory differ-
ences suggest a pathophysiological discrepancy be-
tween the subgroups of patients with narcolepsy. 
Taking into consideration the aforementioned 
studies along with our results, we believe that a se-
lective destruction of cells of the lateral hypothala-
mus via immunological aggression in an early phase 
of the illness, or prior to the onset of symptoms, 
could have occured. This may explain the symptoms 
of frequent cataplexy. Immunosuppressive therapy 
has been used in children and adolescents with early 
diagnosed narcolepsy. Initial results are likely to yield 
promising outcomes21. we posit that the results ob-
tained in this work contribute to and reinforce the hy-
pothesis of narcolepsy as an immunological disease. 
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